SynthesisJournal of affective disorders2020
Development of the Ketamine Side Effect Tool (KSET).
Synthesis in Journal of affective disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 46 citations in OpenAlex.
- Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.The British journal of psychiatry : the journal of mental science · 2023Trial
- Change in Negative Affective Bias following a Single Ketamine Treatment for Treatment-Resistant Depression.Depression and anxiety · 2023Trial
- A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults.Npj mental health research · 2026Article
- Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study.BMJ open · 2026Article
- Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa.Journal of eating disorders · 2025Article
- Safety considerations and risk mitigation strategies for ketamine use: a comprehensive review.Annals of medicine and surgery (2012) · 2025Review
- Rapid treatment center for depression in China: constructive reflections and transnational implications.Frontiers in psychiatry · 2025Review
- Implementation of a ketamine programme for treatment-resistant depression in the public health system: Lessons from the first Australian public hospital clinic.The Australian and New Zealand journal of psychiatry · 2024Article
- Guidelines for ketamine use in clinical psychiatry practice.BJPsych open · 2024Article
- Stereoselective Pharmacokinetics of Ketamine Administered at a Low Dose in Awake Dogs.Animals : an open access journal from MDPI · 2024Article
- Article
- Article
- Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice?British journal of pain · 2023Article
- A systematic review of the print media representation of ketamine treatments for psychiatric disorders.BJPsych open · 2023Review
- Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression.Clinical drug investigation · 2022Article
- The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry.Journal of affective disorders · 2022Article
- Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing.CNS drugs · 2022Article
- Specific Impacts of Ketamine on Bladder Dysfunction and Associated Histological Alterations in Rats-A Time Course Validation through Transmission Electron Microscopy.International journal of molecular sciences · 2022Article
- Ketamine treatment for depression: a review.Discover mental health · 2022Review
- Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.CNS drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 13 institutions in 9 countries.
Funding
Abstract
backgroundCurrently, no specific, systematic assessment tool for the monitoring and reporting of ketamine-related side effects exists. Our aim was to develop a comprehensive Ketamine Side Effect Tool (KSET) to capture acute and longer-term side effects associated with repeated ketamine treatments.
methodsInformed by systematic review data and clinical research, we drafted a list of the most commonly reported side effects. Face and content validation were obtained via feedback from collaborators with expertise in psychiatry and anaesthetics, clinical trial piloting and a modified Delphi Technique involving ten international experts.
resultsThe final version consisted of four forms that collect information at time points: screening, baseline, immediately after a single treatment, and longer-term follow-up. Instructions were developed to guide users and promote consistent utilisation. LIMITATIONS: Further evaluation of feasibility, construct validity and reliability is required, and is planned across multiple international sites.
conclusionsThe structured Ketamine Side Effect Tool (KSET) was developed, with confirmation of content and face validity via a Delphi consensus process. This tool is timely, given the paucity of data regarding ketamine's safety, tolerability and abuse potential over the longer term, and its recent adoption internationally as a clinical treatment for depression. Although based on data from depression studies, the KSET has potential applicability for ketamine (or derivatives) used in other medical disorders, including chronic pain. We recommend its utilisation for both research and clinical scenarios, including data registries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.